| 478 | 4 | 73 |
| 下载次数 | 被引频次 | 阅读次数 |
水疱性口炎病毒（Vesicular stomatitis virus,VSV）是一种在家畜中流行，给畜牧业造成严重经济损失的病毒。然而，随着研究的深入，VSV不仅作为负链RNA病毒的代表种帮助阐明了负链RNA病毒的复制机制，并且随着通过cDNA克隆拯救VSV技术的建立，VSV成为了病毒学研究、疫苗研发及肿瘤治疗的有力工具。本文对VSV的基因组结构、增殖方式、重组VSV的构建技术以及重组VSV在基础研究和临床方面的应用进行了综述。
Abstract：Vesicular stomatitis virus(VSV) causes outbreaks of disease in cattle and results in major economic losses. However, the virus was also served as model species for negative-strand RNA viruses and played a valuable role in elucidating their replication mechanisms. Since the establishment of a reverse genetics system for rescuing infectious VSV from cDNA clones, modification of the VSV genome was feasible. Thus, modified VSV has become a powerful tool in the area of virology, vaccine, and cancer therapy. In this review, we summarized the genome structure, replication cycle and reverse genetic of VSV, and also described its applications in virology.
[1] Mead D G, Ramberg F B, Besselsen D G, Mare C J.Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice[J/OL]. Science, 2000, 287(5452):485-487.DOI:10.1126/science.287.5452.485.
[2] Fields B N, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic[J/OL]. N Engl J Med, 1967, 277(19):989-994.DOI:10.1056/NEJM196711092771901.
[3] Walker P J, Firth C, Widen S G, Blasdell K R,Guzman H, Wood T G, Paradkar P N, Holmes E C,Tesh R B, Vasilakis N. Evolution of genome size and complexity in the rhabdoviridae[J/OL]. PLoS Pathog,2015, 11(2):e1004664. DOI:10.1371/journal.ppat.1004664.
[4] Rodriguez L L, Pauszek S J, Bunch T A, Schumann K R. Full-length genome analysis of natural isolates of vesicular stomatitis virus(Indiana 1 serotype)from North, Central and South America[J/OL]. J Gen Virol, 2002, 83(Pt 10):2475-2483. DOI:10.1099/0022-1317-83-10-2475.
[5] Stillman E A, Whitt M A. Mutational analyses of the intergenic dinucleotide and the transcriptional start sequence of vesicular stomatitis virus(VSV)define sequences required for efficient termination and initiation of VSV transcripts[J/OL]. J Virol, 1997, 71(3):2127-2137.DOI:10.1128/JVI.71.3.2127-2137.1997.
[6] Pattnaik A K, Ball L A, LeGrone A, Wertz G W. The termini of VSV DI particle RNAs are sufficient to signal RNA encapsidation, replication, and budding to generate infectious particles[J/OL]. Virology, 1995,206(1):760-764. DOI:10.1016/s0042-6822(95)80005-0.
[7] Ge P, Tsao J, Schein S, Green T J, Luo M, Zhou Z H. Cryo-EM model of the bullet-shaped vesicular stomatitis virus[J/OL]. Science, 2010, 327(5966):689-693.DOI:10.1126/science.1181766.
[8] Roche S, Rey F A, Gaudin Y, Bressanelli S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G[J/OL]. Science, 2007, 315(5813):843-848.DOI:10.1126/science.1135710.
[9] Green T J, Zhang X, Wertz G W, Luo M. Structure of the vesicular stomatitis virus nucleoprotein-RNA complex[J/OL]. Science, 2006, 313(5785):357-360.DOI:10.1126/science.1126953.
[10]Gould J R, Qiu S, Shang Q, Ogino T, Prevelige P E,Jr., Petit C M, Green T J. The Connector Domain of Vesicular Stomatitis Virus Large Protein Interacts with the Viral Phosphoprotein[J/OL]. J Virol, 2020, 94(6).DOI:10.1128/JVI.01729-19.
[11]Enninga J, Levy D E, Blobel G, Fontoura B M. Role of nucleoporin induction in releasing an mRNA nuclear export block[J/OL]. Science, 2002, 295(5559):1523-1525.DOI:10.1126/science.1067861.
[12]Finkelshtein D, Werman A, Novick D, Barak S,Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus[J/OL]. Proc Natl Acad Sci U S A, 2013, 110(18):7306-7311.DOI:10.1073/pnas.1214441110.
[13]Belot L, Albertini A, Gaudin Y. Structural and cellular biology of rhabdovirus entry[J/OL]. Adv Virus Res,2019, 104:147-183. DOI:10.1016/bs.aivir.2019.05.003.
[14]Mire C E, White J M, Whitt M A. A spatio-temporal analysis of matrix protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating[J/OL].PLoS Pathog, 2010, 6(7):e1000994. DOI:10.1371/journal.ppat.1000994.
[15]Barr J N, Whelan S P, Wertz G W. Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus[J/OL]. Biochim Biophys Acta, 2002, 1577(2):337-353.DOI:10.1016/s0167-4781(02)00462-1.
[16]Iverson L E, Rose J K. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription[J/OL]. Cell, 1981, 23(2):477-484.DOI:10.1016/0092-8674(81)90143-4.
[17]Arnheiter H, Davis N L, Wertz G, Schubert M,Lazzarini R A. Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis[J/OL]. Cell, 1985, 41(1):259-267.DOI:10.1016/0092-8674(85)90079-0.
[18]Lyles D S. Assembly and budding of negative-strand RNA viruses[J/OL]. Adv Virus Res, 2013, 85:57-90.DOI:10.1016/B978-0-12-408116-1.00003-3.
[19]Pattnaik A K, Ball L A, LeGrone A W, Wertz G W.Infectious defective interfering particles of VSV from transcripts of a cDNA clone[J/OL]. Cell, 1992, 69(6):1011-1020.DOI:10.1016/0092-8674(92)90619-n.
[20]Lawson N D, Stillman E A, Whitt M A, Rose J K.Recombinant vesicular stomatitis viruses from DNA[J/OL]. Proc Natl Acad Sci U S A, 1995, 92(10):4477-4481.DOI:10.1073/pnas.92.10.4477.
[21]Whelan S P, Ball L A, Barr J N, Wertz G T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones[J/OL]. Proc Natl Acad Sci U S A,1995, 92(18):8388-8392. DOI:10.1073/pnas.92.18.8388.
[22]Harty R N, Brown M E, Hayes F P, Wright N T,Schnell M J. Vaccinia virus-free recovery of vesicular stomatitis virus[J/OL]. J Mol Microbiol Biotechnol,2001, 3(4):513-517.
[23]Plakhov I V, Arlund E E, Aoki C, Reiss C S. The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system[J/OL]. Virology, 1995, 209(1):257-262.DOI:10.1006/viro.1995.1252.
[24]Shinozaki K, Ebert O, Suriawinata A, Thung S N,Woo S L. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats[J/OL]. J Virol,2005, 79(21):13705-13713. DOI:10.1128/JVI.79.21.13705-13713.2005.
[25]Johnson J E, Nasar F, Coleman J W, Price R E,Javadian A, Draper K, Lee M, Reilly P A, Clarke D K, Hendry R M, Udem S A. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in nonhuman primates[J/OL]. Virology, 2007, 360(1):36-49.DOI:10.1016/j.virol.2006.10.026.
[26]Gray Z, Tabarraei A, Moradi A, Kalani M R. M51and Delta-MR51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells[J/OL].Mol Biol Rep, 2019, 46(3):3371-3379.DOI:10.1007/s11033-019-04799-3.
[27]Day G L, Bryan M L, Northrup S A, Lyles D S,Westcott M M, Stewart J H t. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer[J/OL]. J Surg Res, 2020, 245:127-135.DOI:10.1016/j.jss.2019.07.032.
[28]Ammayappan A, Nace R, Peng K W, Russell S J.Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites[J/OL]. J Virol, 2013, 87(6):3217-3228. DOI:10.1128/JVI.02984-12.
[29]Roberts A, Kretzschmar E, Perkins A S, Forman J,Price R, Buonocore L, Kawaoka Y, Rose J K.Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge[J/OL]. J Virol, 1998, 72(6):4704-4711.DOI:10.1128/JVI.72.6.4704-4711.1998.
[30]Ayala-Breton C, Russell L O, Russell S J, Peng K W.Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus[J/OL]. J Virol, 2014, 88(15):8332-8339.DOI:10.1128/JVI.03823-13.
[31]van den Pol A N, Mao G, Chattopadhyay A, Rose J K,Davis J N. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus:Actions in the Brain[J/OL]. J Virol, 2017, 91(6).DOI:10.1128/JVI.02154-16.
[32]Flanagan E B, Schoeb T R, Wertz G W. Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice[J/OL]. J Virol, 2003, 77(10):5740-5748. DOI:10.1128/jvi.77.10.5740-5748.2003.
[33]van den Pol A N, Davis J N. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity[J/OL]. J Virol, 2013, 87(2):1019-1034. DOI:10.1128/JVI.01106-12.
[34]Carette J E, Raaben M, Wong A C, Herbert A S,Obernosterer G, Mulherkar N, Kuehne A I, Kranzusch P J, Griffin A M, Ruthel G, Dal Cin P, Dye J M,Whelan S P, Chandran K, Brummelkamp T R. Ebola virus entry requires the cholesterol transporter NiemannPick C1[J/OL]. Nature, 2011, 477(7364):340-343.DOI:10.1038/nature10348.
[35]Fukuma A, Tani H, Taniguchi S, Shimojima M, Saijo M, Fukushi S. Inability of rat DPP4 to allow MERSCoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein[J/OL].Arch Virol, 2015, 160(9):2293-2300.DOI:10.1007/s00705-015-2506-z.
[36]Fukushi S, Watanabe R, Taguchi F. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins[J/OL].Methods Mol Biol, 2008, 454:331-338.DOI:10.1007/978-1-59745-181-9_23.
[37]Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM(CDw150)is a cellular receptor for measles virus[J/OL]. Nature, 2000, 406(6798):893-897. DOI:10.1038/35022579.
[38]Slough M M, Chandran K, Jangra R K. Two Point Mutations in Old World Hantavirus Glycoproteins Afford the Generation of Highly Infectious Recombinant Vesicular Stomatitis Virus Vectors[J/OL]. mBio,2019, 10(1).DOI:10.1128/mBio.02372-18.
[39]Kaimori A, Kanto T, Kwang Limn C, Komoda Y, Oki C, Inoue M, Miyatake H, Itose I, Sakakibara M,Yakushijin T, Takehara T, Matsuura Y, Hayashi N.Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin[J/OL].Virology, 2004, 324(1):74-83. DOI:10.1016/j.virol.2004.03.038.
[40]Salvador B, Zhou Y, Michault A, Muench M O,Simmons G. Characterization of Chikungunya pseudotyped viruses:Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein[J/OL].Virology, 2009, 393(1):33-41. DOI:10.1016/j.virol.2009.07.013.
[41]Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein:proteolytic processing, acylation,cell tropism, and detection of neutralizing antibodies[J/OL]. J Virol, 2001, 75(3):1576-1580.DOI:10.1128/JVI.75.3.1576-1580.2001.
[42]Saha M N, Tanaka A, Jinno-Oue A, Shimizu N,Tamura K, Shinagawa M, Chiba J, Hoshino H.Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus[J/OL]. J Virol, 2005, 79(19):12566-12574. DOI:10.1128/JVI.79.19.12566-12574.2005.
[43]Bacsi A, Ebbesen P, Szabo J, Beck Z, Andirko I,Csoma E, Toth F D. Pseudotypes of vesicular stomatitis virus-bearing envelope antigens of certain HIV-1 strains permissively infect human syncytiotrophoblasts cultured in vitro:implications for in vivo infection of syncytiotrophoblasts by cell-free HIV-1[J/OL]. J Med Virol, 2001, 64(4):387-397.DOI:10.1002/jmv.1063.
[44]Abe K, Nozaki A, Tamura K, Ikeda M, Naka K,Dansako H, Hoshino H O, Tanaka K, Kato N.Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes[J/OL]. Microbiol Immunol, 2007, 51(1):117-125.DOI:10.1111/j.1348-0421.2007.tb03882.x.
[45]Porotto M, Carta P, Deng Y, Kellogg G E, Whitt M,Lu M, Mungall B A, Moscona A. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors[J/OL]. J Virol, 2007, 81(19):10567-10574.DOI:10.1128/JVI.01181-07.
[46]Li Qianqian, Wu Jiajing, Nie Jianhui, Zhang Li, Hao Huan, Liu Shuo, Zhao Chenyan, Zhang Qi, Liu Huan,Nie Lingling, Qin Haiyang, Wang Meng, Lu Qiong, Li Xiaoyu, Sun Qiyu, Liu Junkai, Zhang Linqi, Li Xuguang, Huang Weijin, Wang Youchun. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity[J/OL]. Cell, 2020, 182(5):1284-1294 e1289.DOI:10.1016/j.cell.2020.07.012.
[47]Li Qianqian, Nie Jianhui, Wu Jiajing, Zhang Li, Ding Ruxia, Wang Haixin, Zhang Yue, Li Tao, Liu Shuo,Zhang Mengyi, Zhao Chenyan, Liu Huan, Nie Lingling, Qin Haiyang, Wang Meng, Lu Qiong, Li Xiaoyu, Liu Junkai, Liang Haoyu, Shi Yi, Shen Yuelei, Xie Liangzhi, Zhang Linqi, Qu Xiaowang, Xu Wenbo, Huang Weijin, Wang Youchun. SARS-CoV-2501Y. V2 variants lack higher infectivity but do have immune escape[J/OL]. Cell, 2021, 184(9):2362-2371 e2369.DOI:10.1016/j.cell.2021.02.042.
[48]Wang Youchun, Zhang Li, Li Qianqian, Liang Ziteng,Li Tao, Liu Shuo, Cui Qianqian, Nie Jianhui, Wu Qian, Qu Xiaowang, Huang Weijin. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron[J/OL]. Emerg Microbes Infect, 2022, 11(1):1-5.DOI:10.1080/22221751.2021.2017757.
[49]Tian Yabin, Zhao Hui, Liu Qiang, Zhang Chuntao,Nie Jianhui, Huang Weijin, Li Changgui, Li Xuguang,Wang Youchun. Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9virus[J/OL]. Sci Rep, 2018, 8(1):8484. DOI:10.1038/s41598-018-26822-6.
[50]Li Qianqian, Liu Qiang, Huang Weijing, Wu Jiajing,Nie Jianhui, Wang Meng, Zhao Chenyan, Zhang Li,Wang Youchun. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions[J/OL]. Vaccine,2017, 35(38):5172-5178. DOI:10.1016/j.vaccine.2017.07.101.
[51]Konduru K, Shurtleff A C, Bradfute S B, Nakamura S,Bavari S, Kaplan G. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge[J/OL]. PLoS One, 2016, 11(9):e0162446. DOI:10.1371/journal.pone.0162446.
[52]Nie Jianhui, Wu Xiaohong, Ma Jian, Cao Shouchun,Huang Weijin, Liu Qiang, Li Xuguang, Li Yuhua,Wang Youchun. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system[J/OL]. Sci Rep, 2017, 7:42769.DOI:10.1038/srep42769.
[53]Garbutt M, Liebscher R, Wahl-Jensen V, Jones S,Moller P, Wagner R, Volchkov V, Klenk H D,Feldmann H, Stroher U. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses[J/OL]. J Virol, 2004, 78(10):5458-5465. DOI:10.1128/jvi.78.10.5458-5465.2004.
[54]Regules J A, Beigel J H, Paolino K M, Voell J,Castellano A R, Hu Z, Munoz P, Moon J E, Ruck R C, Bennett J W, Twomey P S, Gutierrez R L, Remich S A, Hack H R, Wisniewski M L, Josleyn M D,Kwilas S A, Van Deusen N, Mbaya O T, Zhou Y,Stanley D A, Jing W, Smith K S, Shi M, Ledgerwood J E, Graham B S, Sullivan N J, Jagodzinski L L, Peel S A, Alimonti J B, Hooper J W, Silvera P M, Martin B K, Monath T P, Ramsey W J, Link C J, Lane H C,Michael N L, Davey R T, Jr., Thomas S J, r V-Z-G P S G. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine[J/OL]. N Engl J Med, 2017, 376(4):330-341.DOI:10.1056/NEJMoa1414216.
[55]Henao-Restrepo A M, Camacho A, Longini I M,Watson C H, Edmunds W J, Egger M, Carroll M W,Dean N E, Diatta I, Doumbia M, Draguez B,Duraffour S, Enwere G, Grais R, Gunther S, Gsell P S, Hossmann S, Watle S V, Konde M K, Keita S,Kone S, Kuisma E, Levine M M, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S,Vicari A S, Rottingen J A, Kieny M P. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease:final results from the Guinea ring vaccination, open-label, cluster-randomised trial(Ebola Ca Suffit!)[J/OL]. Lancet, 2017, 389(10068):505-518.DOI:10.1016/S0140-6736(16)32621-6.
[56]Khurana S, Fuentes S, Coyle E M, Ravichandran S,Davey R T, Jr., Beigel J H. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies[J/OL]. Nat Med,2016, 22(12):1439-1447.DOI:10.1038/nm.4201.
[57]Feldmann H, Jones S M, Daddario-DiCaprio K M,Geisbert J B, Stroher U, Grolla A, Bray M, Fritz E A,Fernando L, Feldmann F, Hensley L E, Geisbert T W.Effective post-exposure treatment of Ebola infection[J/OL]. PLoS Pathog, 2007, 3(1):e2. DOI:10.1371/journal.ppat.0030002.
[58]Rose N F, Marx P A, Luckay A, Nixon D F, Moretto W J, Donahoe S M, Montefiori D, Roberts A,Buonocore L, Rose J K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants[J/OL]. Cell, 2001, 106(5):539-549.DOI:10.1016/s0092-8674(01)00482-2.
[59]Emanuel J, Callison J, Dowd K A, Pierson T C,Feldmann H, Marzi A. A VSV-based Zika virus vaccine protects mice from lethal challenge[J/OL]. Sci Rep,2018, 8(1):11043.DOI:10.1038/s41598-018-29401-x.
[60]Yahalom-Ronen Y, Tamir H, Melamed S, Politi B,Shifman O, Achdout H, Vitner E B, Israeli O, Milrot E, Stein D, Cohen-Gihon I, Lazar S, Gutman H,Glinert I, Cherry L, Vagima Y, Lazar S, Weiss S, Ben-Shmuel A, Avraham R, Puni R, Lupu E, Bar-David E, Sittner A, Erez N, Zichel R, Mamroud E, Mazor O, Levy H, Laskar O, Yitzhaki S, Shapira S C, Zvi A, Beth-Din A, Paran N, Israely T. A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge[J/OL]. Nat Commun,2020, 11(1):6402.DOI:10.1038/s41467-020-20228-7.
[61]Shi Zhongcheng, Cai Zhenyu, Sanchez A, Zhang Tingting, Wen Shu, Wang Jun, Yang Jianhua, Fu Songbin, Zhang Dekai. A novel Toll-like receptor that recognizes vesicular stomatitis virus[J/OL]. J Biol Chem, 2011, 286(6):4517-4524. DOI:10.1074/jbc.M110.159590.
[62]Hornung V, Ellegast J, Kim S, Brzozka K, Jung A,Kato H, Poeck H, Akira S, Conzelmann K K, Schlee M, Endres S, Hartmann G. 5'-Triphosphate RNA is the ligand for RIG-I[J/OL]. Science, 2006, 314(5801):994-997.DOI:10.1126/science.1132505.
[63]Weidner J M, Jiang D, Pan X B, Chang J, Block T M,Guo J T. Interferon-induced cell membrane proteins,IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms[J/OL]. J Virol, 2010,84(24):12646-12657.DOI:10.1128/JVI.01328-10.
[64]Wang B X, Rahbar R, Fish E N. Interferon:current status and future prospects in cancer therapy[J/OL]. J Interferon Cytokine Res, 2011, 31(7):545-552.DOI:10.1089/jir.2010.0158.
[65]Ahmed M, Lyles D S. Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III[J/OL]. J Virol, 1998,72(10):8413-8419. DOI:10.1128/JVI. 72.10.8413-8419.1998.
[66]Faria P A, Chakraborty P, Levay A, Barber G N,Ezelle H J, Enninga J, Arana C, van Deursen J,Fontoura B M. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway[J/OL]. Mol Cell, 2005, 17(1):93-102.DOI:10.1016/j.molcel.2004.11.023.
[67]Altomonte J, Wu L, Meseck M, Chen L, Ebert O,Garcia-Sastre A, Fallon J, Mandeli J, Woo S L.Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells[J/OL]. Cancer Gene Ther, 2009, 16(3):266-278.DOI:10.1038/cgt.2008.74.
[68]Bommareddy P K, Shettigar M, Kaufman H L.Integrating oncolytic viruses in combination cancer immunotherapy[J/OL]. Nat Rev Immunol, 2018, 18(8):498-513.DOI:10.1038/s41577-018-0014-6.
[69]Hastie E, Cataldi M, Steuerwald N, Grdzelishvili V Z.An unexpected inhibition of antiviral signaling by virusencoded tumor suppressor p53 in pancreatic cancer cells[J/OL]. Virology, 2015, 483:126-140.DOI:10.1016/j.virol.2015.04.017.
[70]Fernandez M, Porosnicu M, Markovic D, Barber G N.Genetically engineered vesicular stomatitis virus in gene therapy:application for treatment of malignant disease[J/OL]. J Virol, 2002, 76(2):895-904.DOI:10.1128/jvi.76.2.895-904.2002.
[71]Ebert O, Shinozaki K, Kournioti C, Park M S, GarciaSastre A, Woo S L. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer[J/OL]. Cancer Res, 2004, 64(9):3265-3270.DOI:10.1158/0008-5472.can-03-3753.
[72]Shin E J, Wanna G B, Choi B, Aguila D, 3rd, Ebert O, Genden E M, Woo S L. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma[J/OL]. Laryngoscope,2007, 117(2):210-214.DOI:10.1097/01.mlg.0000246194.66295.d8.
[73]Stephenson K B, Barra N G, Davies E, Ashkar A A,Lichty B D. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity[J/OL]. Cancer Gene Ther, 2012, 19(4):238-246. DOI:10.1038/cgt.2011.81.
[74]Pulido J, Kottke T, Thompson J, Galivo F,Wongthida P, Diaz R M, Rommelfanger D, Ilett E,Pease L, Pandha H, Harrington K, Selby P, Melcher A, Vile R. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma[J/OL]. Nat Biotechnol, 2012, 30(4):337-343.DOI:10.1038/nbt.2157.
[75]O'Donnell K L, Gourdine T, Fletcher P, Clancy C S,Marzi A. Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins[J/OL]. Front Immunol, 2022, 13:1025500. DOI:10.3389/fimmu.2022.1025500.
[76]Taddeo A, Veiga I B, Devisme C, Boss R, Plattet P,Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Optimized intramuscular immunization with VSVvectored spike protein triggers a superior immune response to SARS-CoV-2[J/OL]. NPJ Vaccines,2022, 7(1):82.DOI:10.1038/s41541-022-00508-7.
[77]Hoff N A, Bratcher A, Kelly J D, Musene K,Kompany J P, Kabamba M, Mbala-Kingebeni P,Dighero-Kemp B, Kocher G, Elliott E, Reilly C,Halbrook M, Ilunga Kebela B, Gadoth A, Ngoie Mwamba G, Tambu M, McIlwain D R, Mukadi P,Hensley L E, Ahuka-Mundeke S, Rutherford G W,Muyembe-Tamfum J J, Rimoin A W. Immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo[J/OL]. Proc Natl Acad Sci U S A, 2022, 119(6). DOI:10.1073/pnas.2118895119.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004403
中图分类号:Q939.4
引用信息:
[1]吴曦,王佑春,黄维金.重组水疱性口炎病毒的改造策略及在病毒学研究中的应用进展[J].病毒学报,2023,39(06):1747-1756.DOI:10.13242/j.cnki.bingduxuebao.004403.
基金信息:
国家重点研发计划（项目号：2021YFC0863300）,题目：新型冠状病毒变异监测及功能影响分析~~
2023-10-26
2023-10-26
2023-10-26